The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted therapies, the promise of off-the-shelf chimeric antigen receptor (CAR) ...
Five hundred forty-two specimens of 150 children enrolled in the AML-Berlin-Frankfurt-Muenster (BFM) 98 study were analyzed by four-color immunophenotyping at up to four predefined time points during ...
Early clearance of measurable residual disease (MRD) after induction therapy in patients with acute myeloid leukemia (AML) is associated with significantly better relapse-free survival (RFS) than ...
In this three-part webinar series, we invite you to explore the benefits of a standardized workflow in leukemia and lymphoma analysis. Join this showcase of Beckman Coulter’s new DxFLEX flow cytometer ...
The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.
Our lab studies cell signaling and epigenetic pathways in an aggressive form of bone marrow cancer called acute myeloid leukemia (AML). Our primary focus is on a subtype of AML with mutations in FLT3, ...
News-Medical.Net on MSN
Combination therapy offers hope for AML patients facing drug resistance
A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback